12/5/2016
Vaccinex Featured in a Press Release from the Society for Immunotherapy of Cancer (SITC)
10/6/2016
Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer
9/9/2016
Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial
8/23/2016
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
8/1/2016
Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease
1/5/2016
Vaccinex Inc. Completes Enrollment of Cohort A in its SIGNAL Clinical Trial, a Randomized Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503 in Subjects at Risk for or with Early Signs of Huntington’s Disease
10/30/2015
Vaccinex provided corporate sponsorship and presented information on its current SIGNAL clinical trial (phase 2 trial of VX15 antibody in Huntington’s disease) at the 2015 Huntington Study Group Annual Meeting in Tampa, Fl.
10/28/2015
Vaccinex Announces Publication of Vaccinex-Authored Review of SEMA4D in Oncoimmunology
10/27/2015
Vaccinex to present its ActivMAb® Antibody Discovery Technology at the 2015 PEGS Europe Summit
10/20/2015
Vaccinex announces publication of results from a Phase I trial of anti-Semaphorin 4D antibody, VX15/2503, in patients with advanced solid tumors
10/6/2015
Vaccinex announces publication on the generation, characterization and preclinical evaluation of its lead clinical-stage antibody VX15/2503
6/24/2015
Vaccinex, Inc. announces the initiation of a Phase 2 clinical trial of its investigational VX15/2503 antibody in Huntington’s disease (the SIGNAL trial)
5/11/2015
Vaccinex Announces Publication of VX15/2503 Non-clinical Toxicology Studies
4/27/2015
Vaccinex Publishes Information about its Novel Anti-CXCL13 Antibody for Autoimmune Disease
4/13/2015
Vaccinex to Present Preclinical Anti-Semaphorin 4D Data at AACR
4/1/2015
Vaccinex Provides an Update on Its VX15/2503 Phase 1 Clinical Trial in Multiple Sclerosis Patients
3/19/2015
Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
2/17/2015
Vaccinex announces the publication of data demonstrating preclinical efficacy in an animal model of Huntington Disease
1/26/2015
Vaccinex announces groundbreaking preclinical data demonstrating an immunomodulatory role for anti-SEMA4D antibody blockade in colon and breast cancer
12/12/2014
Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease
12/9/2014
Vaccinex provides an update on its VX15/2503 Phase 1 clinical trial in cancer patients
12/3/2014
Vaccinex to present its ActivMAb® Antibody Discovery Technology at the 2014 IBC Antibody Engineering & Therapeutics Conference
12/2/2014
Vaccinex enters into a research collaboration with Janssen R&D for the creation of novel anti-cancer agents
11/18/2014
Vaccinex Presented its ActivMAb® Antibody Discovery Technology at the 2014 PEGS Europe Summit
6/16/2014
Vaccinex Presented data on VX15/2503 at American Society of Clinical Oncology (ASCO) 2014 Conference
5/12/2014
Vaccinex Appoints Steve Cobourn, C.P.A. as Chief Financial Officer
10/4/2013
Vaccinex Presented data on VX15/2503 at CRI Cancer Immunotherapy 2013 Conference
10/4/2013
Vaccinex Presented VX15 Preclinical MS Data at the 2013 ECTRIMS Annual Conference
5/28/2013
Vaccinex Appoints Valerie Iddison, M.D. as Chief Medical Officer
1/7/2013
Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients
12/10/2012
Vaccinex Presented Antibody Selection Technology at the 2012 IBC Antibody Engineering and Antibody Therapeutics Conference
10/10/2012
Vaccinex to Present VX15 and VX5 Preclinical MS Data at the 2012 ECTRIMS Annual Conference
5/15/2012
Vaccinex Presented at the American Association for Cancer Research (AACR) Annual Conference
9/8/2011
Vaccinex to Present VX15 Preclinical MS Data at the 2011 ECTRIMS Annual Conference
8/8/2011
New BioCentury article discussing remyelinating agents in multiple sclerosis
4/1/2011
Vaccinex To Present at the American Association for Cancer Research (AACR) and the American Academy of Neurology (AAN) Annual Conferences
3/9/2011
Vaccinex To Present at the 2011 BIO-Windhover Pharmaceutical Strategic Outlook Conference
1/4/2011
Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients with Advanced Solid Tumors
11/2/2010
Vaccinex, Inc. awarded three Qualifying Therapeutic Discovery Project (QTDP) grants under the Patient Protection and Affordable Care Act of 2010 (PPACA)
10/4/2010
Vaccinex To Present at the 4th Annual Therapeutic Monoclonal Antibody Discovery Conference
5/10/2010
Vaccinex To Present at the 6th Annual PEGS Protein Engineering Summit